Publication
Identification of fusions with potential clinical significance in melanoma.
Authors not recorded
- Source
- PubMed
- Retrieved
- Sep 11, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260911-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
Linked entities
Linked entities (8)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 8
- cancerCutaneous Melanomacivic_curation1.00
- cancerMelanomacivic_curation1.00
- drugBinimetinibcivic_curation1.00
- drugTrametinibcivic_curation1.00
- geneBRAFcivic_curation1.00
- geneRAF1civic_curation1.00
- variantBRAF Fusioncivic_curation1.00
- variantRAF1 Fusioncivic_curation1.00
Curated evidence
Evidence citing this paper (2)
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 35871080
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| BRAF Fusion1 | ||||||||
| Trametinib | Cutaneous MelanomaALIAS | Predictive | C | Supports Sensitivity Response | 2 | accepted | EID13150A 42 year old male patient with stage III cutaneous melanoma harboring an AGAP3::BRAF fusion was treated with the MEK inhibitor trametinib after prior pembrolizumab and experienced a response lasting … (full text at CIViC) PMID 35871080 · Moran et al., 2022 · Open in CIViC | civic |
| RAF1 Fusion1 | ||||||||
| Binimetinib | Cutaneous MelanomaALIAS | Predictive | C | Supports Sensitivity Response | 2 | accepted | EID13149A 51 year old male patient with metastatic cutaneous melanoma harboring a RUFY1::RAF1 fusion received the MEK inhibitor binimetinib after prior pembrolizumab and ipilimumab/nivolumab. During four mont… (full text at CIViC) PMID 35871080 · Moran et al., 2022 · Open in CIViC | civic |